Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
22 results
D2.271 - The effect of Organic Light Emiting Diode(OLED) phototherapy in atopic mouse model
D2.274 - Late-onset toxic epidermal necrolysis (TEN) associated with nivolumab: attention to possible cofactors
D2.261 - Mental health and quality of life in patients with chronic spontaneous urticaria
D2.265 - Standard dosage vs. increased dosage of non-sedating antihistamines in pharmacotherapy of chronic spontaneous urticaria
D2.266 - Comparative Efficacy of Dupilumab, Janus Kinase Inhibitors, and Conventional Immunosuppressants on Neuropsychiatric Outcomes in Patients with Atopic Dermatitis: A Retrospective Cohort Study
D2.267 - Real-World Clinical Outcomes of Chronic Urticaria Patients in Greece: Longitudinal Data from the CURE Registry
D2.268 - Clinical characteristics and Therapeutic Management of Hereditary Angioedema due to C1-Inhibitor Deficiency: A Retrospective Cohort Study in Colombia
D2.269 - Predictors of Poor Disease Control in Greek Patients with Chronic Urticaria: Real-World Evidence from the CURE Registry
D2.270 - Clinical and Laboratory predictors of treatment response among adult Egyptian patients with Chronic Spontaneous Urticaria
D2.272 - Long-Term Remission Patterns in Chronic Spontaneous Urticaria: A Real-Life Cohort Study
D2.273 - The frequency of metal sensitisation in patients who are about to undergo joint replacement
D1.437 - A Decade of Research on Janus Kinase Inhibitors in Atopic Dermatitis: A Global Bibliometric Analysis (2015–2024)
D1.438 - Dupilumab for Moderate-to-Severe Atopic Dermatitis in Children and Adolescents: Real-Life Assessment of Efficacy and Safety
D1.442 - Design and Preclinical Development of a Bispecific Antibody Targeting IL11 and TL1A
D1.443 - Preclinical Development of a Dual LIGHT/TL1A Bispecific Antibody
D1.446 - Lebrikizumab in patients with urticarial vasculitis - a case series
D1.447 - Comparison of Disease Duration, Remission, and Other Disease-Related Parameters with the Duration of Omalizumab Treatment in Patients with Chronic Spontaneous Urticaria
D1.448 - Long-Term Efficacy and Stability of Lebrikizumab in Treating Face/Head and Neck Involvement in Patients with Moderate-to-Severe Atopic Dermatitis
D1.449 - A Phase 2, Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Briquilimab in Adults with Chronic Urticaria (Trial in Progress)
D1.439 - Urticaria Voices: Physician-reported perspectives of chronic urticaria care and its treatment in China (UV in China)
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download